| 0.07 Data as of May 17 |  -0.01 / -12.50%Today’s Change | 0.06 Today|||52-Week Range 3.02 | -97.53% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Biotechnology | MARKET CAP $2.4M |
Company Description
Myrexis, Inc. is a biopharmaceutical company. It focuses on identifying, evaluating and acquiring commercial-stage biopharmaceutical assets. The company has a pipeline of differentiated product candidates in oncology and autoimmune diseases. Myrexis's oncology programs currently have two active programs: Hsp90 Inhibitor Program and Cancer Metabolism Inhibitor Program. The Hsp90 Inhibitor Program is an MPC-3100, a phase I clinical trial product candidate for cancer treatment. The Cancer Metabolism Inhibitor Program is an MPC-8640, a preclinical compound for the Cancer Metabolism Inhibitor program and is being developed by Myrexis as a drug candidate for the treatment of a variety of cancers. Myrexis was founded in January 2009 and is headquartered in Salt Lake City, UT.
Employees
Shareholders
| Mutual fund holders | 7.53% |
| Individual stakeholders | 38.97% |
| Other institutional | 20.26% |
Top Executives
| Jonathan Couchman | Chairman, President & Chief Executive Officer |
| Andrea E. Kendell | Chief Financial Officer, Secretary & Treasurer |
| Andrew Beelen | Vice President-Clinical Research |
| Kenton H. Zavitz, PhD | Senior Director-Clinical Affairs |
| Gradon D. Knotts, MBA | Vice President-Business Development |
.
